Mononuclear phagocytes in the graft . This has impact on the inflammatory process, since recent studies show that TNF activates neutrophils 14, 15 ; , enhances prostaglandin production 16 ; , stimulates production of procoagulant activity 17, 18 ; , stimulates fibroblast growth 19 ; , and increases the surface expression of class I major histocompatibility complex antigens 20 ; . Moreover, TNF is a potent pyrogen 21 ; and regulates the hepatic acute-phase protein gene expression 22 ; . Thus, several of the local and systemic manifestations observed in patients with acute renal allograft rejection could be explained on the basis of TNF release . In fact, the question arises whether the release of TNF from the activated mononuclear phagocytes is a primary event, since under experimental conditions TN F production may amount to -I% of the total secretory products of macrophages 5 ; , and TNF has been shown to induce the release of IL-1 from monocytes 21 ; and endothelial cells 23 ; . Glucocorticoids are known to inhibit TNF gene transcription and prevent its synthesis 1, 24 ; . The transplant patients received methylprednisolone and azathioprine as basic immunosuppression, and rejection episodes were managed by increasing the methylprednisolone dosage, so medication may have influenced the absolute levels of TNF . In a few patients, a rapid decline in TNF levels was noted after starting the high-dose steroid regimen, which could be explained by a direct suppression of TNF synthesis . Two recent studies in man have demonstrated elevated levels of TNF in infectious diseases . Scuderi et al . using an enzyme immunoassay, found a mean TNF level of 119 pg ml in patients with kala-azar and malaria, and Waage et al . using a bioassay, found raised TNF levels in patients with septic meningococcal disease . In the septicemic patients, serum TNF levels over 440 U ml corresponding to 100 pg ml ; were associated with a poor outcome . It is noteworthy that the peak levels of TNF during renal allograft rejection median 140 pg ml ; , as measured by radioimmunoassay, were in the same concentration range as seen during the infectious states . Thus the release of TNF into circulation in man is not confined to severe bacterial and parasitic infections, but occurs also as a result of noninfectious immunologic tissue injury . Our results are compatible with the view that TNF, like IL-1, is a reglutary monokine that has a basic function as a mediator of inflammation . Summary A sensitive radioimmunoassay was used for monitoring serum levels of endogenous cachectin tumor necrosis factor a TNF ; in 10 renal transplant recipients . Acute allograft rejections were associated with marked elevations of circulating TNF . The peak levels of TNF median 140 pg ml ; were in the same concentration range as previously reported in parasitic infections. The results show that the release of TNF into circulation is an early event in renal allograft rejection and that raised levels of TNF in man can also be induced by noninfectious stimuli . We thank Dr . J Ahonen, Transplantation Unit, Fourth Department of Surgery, Helsinki University Central Hospital, for his cooperation.
Comments Ankylosing Spondylitis and Other Spondyloarthropathies: Recipient has had an inadequate response to: o NSAIDS, unless contraindicated AND o DMARDs sulfasalazine, corticosteroids, azathioprine, cyclosporine, cyclophosphamide ; AND o Methotrexate AND o Preferred biologics approved for this indication. Moderate to severe ulcerative colitis refractory to one or more of the following standard therapies: Corticosteroids e.g, prednisone, methylprednisolone ; 5-aminosalicylic acid agents e.g., sulfasalazine, mesalamine, balsalazide ; Immunosuppressants e.g., azathioprine, cyclosporine, 6mercaptopurine ; . For Amevive: Recipient has failed to adequately respond to or is intolerant to a three or more month trial of one of the following photochemotherapies unless contraindicated ; : o o psoralens methoxsalen, trioxsalen ; with UVA light PUVA OR UVB with coal tar or dithranol; AND Preferred biologics indicated for this diagnosis AND Recipient has not already been receiving Amevive therapy for duration of 12 months or more and nasonex. LIST OF NEW AND REVISED PROTOCOLS The INDEX to BC Cancer Agency Protocol Summaries is revised monthly includes tumour group, protocol code, indication, drugs, last revision date and version ; . Protocol codes for treatments requiring "Undesignated Indication" approval are prefixed with the letter U. U ; GOOVVIN revised days for CBC and diff clarified ; : Palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer using vinorelbine GUVIP2 revised dosing time and etoposide infusion time clarified ; : Nonseminoma consolidation salvage protocol using etoposide, cisplatin, ifosfamide, mesna U ; MYBORTEZ revised clarification of baseline tests and dose modification for diarrhea, dose level for diarrhea table deleted ; : Treatment of multiple myeloma with bortezomib MYHDC revised contact physician, tests, prehydration and filgrastim dose revised ; : Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant Protocols are available on the BC Cancer Agency website bccancer.bc ChemoProtocols ; under Health Professionals Info, Chemotherapy Protocols. PRE-PRINTED ORDER UPDATE Pre-printed orders should always be checked with the most current BC Cancer Agency protocol summaries. The BC Cancer Agency Vancouver Centre has prepared chemotherapy pre-printed orders, which can be used as a guide for reference. An index to the orders can be obtained by Fax-back. BRAJACT revised methylprednisolone replaced by hydrocortisone for hypersensitivity management ; : Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel BRAVCAD revised methylprednisolone replaced by hydrocortisone for hypersensitivity management ; : Palliative Therapy for metastatic breast cancer using docetaxel and capecitabine BRAVDOC revised methylprednisolone replaced by hydrocortisone for hypersensitivity management ; : Palliative therapy for metastatic breast cancer using docetaxel Taxotere ; BRAVDOC7 revised methylprednisolone replaced by hydrocortisone for hypersensitivity management ; : Palliative therapy for metastatic breast cancer using weekly docetaxel Taxotere ; BRAVTAX revised dilution volume for low dose of paclitaxel ; : Palliative therapy for metastatic breast cancer using paclitaxel BRAVTRAP revised dilution volume for low dose of paclitaxel ; : Palliative therapy for metastatic breast cancer using trastuzumab Herceptin ; and paclitaxel as first-line treatment for recurrent breast cancer refractory to anthracycline chemotherapy GOOVTAX3 revised methylprednisolone replaced by hydrocortisone for hypersensitivity management ; : Treatment of progressive, platinum-refractory epithelial ovarian carcinoma, primary peritoneal carcinoma or fallopian tube carcinoma using paclitaxel U ; GOOVVIN revised days for CBC and diff clarified ; : Palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer using vinorelbine GOSMCC2 revised methylprednisolone replaced by hydrocortisone for hypersensitivity management ; : Treatment of small cell carcinoma of cervix using paclitaxel, cisplatin, etoposide and carboplatin with radiation U ; GUTAXGEM revised dilution volume for low dose of paclitaxel ; : Palliative Therapy for germ cell cancers using paclitaxel and gemcitabine LUPG revised random glucose added to lab section ; : Treatment of non-small cell lung cancer and malignant mesothelioma with cisplatin and gemcitabine.
Synopsis According to a report by the BMA's Board of Science on the effects of smoking on reproductive health, around 120, 000 British men may be sexually impotent in the prime of life because of smoking. The report warned that smoking damages men's sperm and in women, also impairs fertility and brings on an early menopause. In addition, carcinogens in tobacco smoke could cause genetic mutations, and this damage could persist in embryos. Women who smoked reduced their chances of conceiving by 10 to 40% and reached menopause two years before non-smokers. The more cigarettes smoked, the greater the risk of early menopause and neurontin. Tier 1 drugs 1 ; are in BLACK and have the number 1 in parenthesis after the name. Tier 2 drugs 2 ; are in all BLUE CAPITAL letters and have the number 2 in parenthesis after the name Tier 3 drugs 3 ; are in all RED CAPITAL letters and have the number 3 in parenthesis after the name. Although these drugs have similar effects, there are some differences in adverse reactions and norvasc. Other Highly Protein-Bound Drugs -- In the osteoporosis treatment trial, there were no clinically relevant effects of co-administration of other highly protein-bound drugs e.g., gemfibrozil ; on plasma concentrations of raloxifene. In vitro, raloxifene did not interact with the binding of phenytoin, tamoxifen, or warfarin see above ; [see Drug Interactions 7.3 ; ]. Ampicillin and Amoxicillin -- Peak concentrations of raloxifene and the overall extent of absorption are reduced 28% and 14%, respectively, with co-administration of ampicillin. These reductions are consistent with decreased enterohepatic cycling associated with antibiotic reduction of enteric bacteria. However, the systemic exposure and the elimination rate of raloxifene were not affected. In the osteoporosis treatment trial, coadministration of amoxicillin had no discernible differences in plasma raloxifene concentrations [see Drug Interactions 7.5 ; ]. Antacids -- Concomitant administration of calcium carbonate or aluminum and magnesium hydroxidecontaining antacids does not affect the systemic exposure of raloxifene [see Drug Interactions 7.5 ; ]. Corticosteroids -- The chronic administration of raloxifene in postmenopausal women has no effect on the pharmacokinetics of methylprednisolone given as a single oral dose [see Drug Interactions 7.5 ; ]. Digoxin -- Raloxifene has no effect on the pharmacokinetics of digoxin [see Drug Interactions 7.5 ; ]. Cyclosporine -- Concomitant administration of EVISTA with cyclosporine has not been studied. Lipid-lowering agents -- Concomitant administration of EVISTA with lipid-lowering agents has not been studied. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis -- In a 21-month carcinogenicity study in mice, there was an increased incidence of ovarian tumors in female animals given 9 to 242 mg kg, which included benign and malignant tumors of granulosa theca cell origin and benign tumors of epithelial cell origin. Systemic exposure AUC ; of raloxifene in this group was 0.3 to 34 times that in postmenopausal women administered a 60 mg dose. There was also an increased incidence of testicular interstitial cell tumors and prostatic adenomas and adenocarcinomas in male mice given 41 or 210 mg kg 4.7 or 24 times the AUC in humans ; and prostatic leiomyoblastoma in male mice given 210 mg kg. In a 2-year carcinogenicity study in rats, an increased incidence in ovarian tumors of granulosa theca cell origin was observed in female rats given 279 mg kg approximately 400 times the AUC in humans ; . The female rodents in these studies were treated during their reproductive lives when their ovaries were functional and responsive to hormonal stimulation. Mutagenesis -- Raloxifene HCl was not genotoxic in any of the following test systems: the Ames test for bacterial mutagenesis with and without metabolic activation, the unscheduled DNA synthesis assay in rat hepatocytes, the mouse lymphoma assay for mammalian cell mutation, the chromosomal aberration assay in Chinese hamster ovary cells, the in vivo sister chromatid exchange assay in Chinese hamsters, and the in vivo micronucleus test in mice. Impairment of Fertility -- When male and female rats were given daily doses 5 mg kg 0.8 times the human dose based on surface area, mg m2 ; prior to and during mating, no pregnancies occurred. In male rats, daily doses up to 100 mg kg 16 times the human dose based on surface area, mg m2 ; for at least 2 weeks did not affect sperm production or quality or reproductive performance. In female rats, at doses of 0.1 to 10 mg kg day 0.02 to 1.6 times the human dose based on surface area, mg m2 ; , raloxifene disrupted estrous cycles and inhibited ovulation. These effects of raloxifene were reversible. In another study in rats in which raloxifene was given during the preimplantation period at doses 0.1 mg kg 0.02 times the human dose based on surface area, mg m2 ; , raloxifene delayed and disrupted embryo implantation, resulting in prolonged gestation and reduced litter size. The reproductive and developmental effects observed in animals are consistent with the estrogen receptor activity of raloxifene. 13.2 Animal Toxicology and or Pharmacology The skeletal effects of raloxifene treatment were assessed in ovariectomized rats and monkeys. In rats, raloxifene prevented increased bone resorption and bone loss after ovariectomy. There were positive effects of raloxifene on bone strength, but the effects varied with time. Cynomolgus monkeys were treated with raloxifene or. This article full text pdf ; alert me when this article is cited alert me if a correction is posted similar articles in this journal similar articles in pubmed alert me to new issues of the journal download to citation manager cited by other online articles reprints and permissions articles by rohatagi, s articles by derendorf, h articles citing this article search for related content pubmed citation articles by rohatagi, s articles by derendorf, h articles pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration s rohatagi, j barth, h mollmann, g hochhaus, a soldner, c mollmann, and h derendorf the pharmacokinetics of methylprednisolone and prednisolone were evaluated in 24 healthy men after oral administration of single and multiple doses for 3 days and ortho and methylprednisolone.
Drug Name Adult Dose Pediatric Dose Contraindications Methylprednisolone Solu-Medrol, Depo-Medrol ; -- By reversing increased capillary permeability and suppressing PMN activity, may decrease inflammation. May also prevent neuronal damage by inhibiting prostaglandin synthesis. 30 mg kg IV bolus initial, followed by 5.4 mg kg h IV Administer as in adults Documented hypersensitivity; viral, fungal, or tubercular skin infections Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels of methylprednisolone; phenobarbital, phenytoin, and rifampin may decrease levels of methylprednisolone adjust dose monitor patients for hypokalemia when taking medication concurrently with diuretics C - Safety for use during pregnancy has not been established. Hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections are possible complications of glucocorticoid use. Kiprov DD, Hofmann JC. Division of Immunotherapy, California Pacific Medical Center and the Bay Area Mobile Apheresis Program, San Francisco, California, USA. dkiprovcai aol . "Plasmapheresis in immunologically mediated polyneuropathies." Therap Apher Dial. 2003 Apr; 7 2 ; : 189-96. Review. 2 ; The Guillain-Barre' Syndrome Study Group. "The North American study of plasmapheresis in the Guillain-Barre syndrome." J Clin Apheresis. 1985; 2 4 ; : 315-20. 3 ; French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. "Plasma exchange in Guillain-Barre syndrome: one-year follow-up." Ann Neurol. 1992 Jul; 32 1 ; : 94-7. 4 ; Dutch Guillain-Barre study group. "Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome." J Neurol Neurosurg Psychiatry. 1998 Feb; 64 2 ; : 242-4. 5 ; "Plasma exchange versus intravenous immunoglobulin for GuillainBarre syndrome." Ther Apher. 1997 May; 1 2 ; : 129-30. 6 ; "High dose intravenous immune globulins and plasma exchange in Guillain-Barre Syndrome." Ital J Neurol Sci. 1995 Oct; 16 7 ; : 487-92. 7 ; The Dutch Guillain-Barre Study Group. "Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study." Ann Neurol. 1994 Jun; 35 6 ; : 74952. Erratum in: Ann Neurol 1994 Sep; 36 3 ; : 457. 8 ; Kincaid JC. "Apheresis in Treatment of the Inflammatory Demyelinating Peripheral Neuropathies." Ther Apher. 2002 6 1 ; : 5356 and oxycodone.

Effect of pre- or posttreatment with methylprednisolone on the myocardial 0-glucuronidase activity top ; and the cathepsin D activity bottom ; of normal or ischemic myocardium. In cats given vehicle, myocardial ischemia MI ; resulted in a 33% reduction in the activity of fj-glucuronidase and a 41% decrease in the activity of cathepsin D from ischemic ventricle relative to that from adjacent normal myocardium. Pre- or posttreatment of cats with methylprednisolone prevented these decreases in the activities of the lysosomal acid hydrolases in acute myocardial ischemia.
Increase in plasma CPK activity 3 hours after occlusion of the left anterior descending coronary artery in dogs. In cats, we found a significant increase in plasma CPK activity 2 hours after occlusion, which progressively increased over the next 3 hours. In contrast to the plasma CPK activity, the plasma activities of the lysosomal acid hydrolases, cathepsin D and S-glucuronidase, did not increase in either sham-operated cats or cats subjected to myocardial ischemia. These findings are not surprising since Glenn et al. 16 ; have shown that plasma lysosomal hydrolases are normally rapidly cleared by the action of the reticuloendothelial cells in the liver and spleen. During severe hypotension or in protracted shock, this clearance mechanism is impaired and lysosomal hydrolases accumulate in peripheral plasma. Such was not the case in our model of myocardial ischemia. However, we did observe a decrease in myocardial lysosomal enzymes and an increase in fragility of myocardial lysosomes in myocardial ischemia. These findings are consistent with the observations in dogs of Ricciutti 17, 18 ; . Thus, it is possible to demonstrate early changes in the activities of cardiac enzymes in ischemic cardiac tissue. However, treatment with methylprednisolone prevented the decreases in cardiac enzyme activities and significantly prevented the increase in plasma CPK activity found following coronary artery occlusion. Moreover, administration of methylprednisolone was associated with a decline in the elevation of the S-T segment of ischemic hearts 2-5 hours after occlusion associated with the preservation of myocardial CPK activity. In this regard, posttreatment with glucocorticoid appeared to be as effective as pretreatment in normalizing the electrical potential of the myocardium. Some degree of reversible damage of cardiac cells occurs between 20 minutes and 2 hours of experimental myocardial infarction in the absence of any therapeutic intervention 5 ; . However, after 2 hours of ischemia, progressive damage occurs which might be difficult to reverse. Since the biological half-life of methylprednisolone in plasma is about 80 minutes 19 ; , it is likely that administration of methylprednisolone 60 minutes after occlusion provides a higher plasma concentration of glucocorticoid than pretreatment at the potentially critical time i.e., about 2 hours after occlusion ; when ischemic cellular alterations would tend to be most severe. Libby et al. 4 ; have reported that administration of pharmacologic amounts of hydrocortisone up to 6 hours after experimental myocardial infarction in dogs reduces.
Generic Name Methylprednisolone Anti-inflammatory Steroid Dosage Form Tablets: 2 mg pink, #Upjohn 49 ; , 4 mg white, #Upjohn 56 ; , 8 mg orange, #Upjohn 22 ; , 16 mg white, #Upjohn 73 ; , 24 mg yellow, #Upjohn 155 ; , and 32 mg orange, #Upjohn 176 ; Topical * : 0.25% and 1.0% as methylprednisolone acetate ; Injection Depo-Medrol ; * : 20 mg ml, 40 mg ml and 80 mg ml as methylprednisolone acetate suspension ; Dosage Ranges Treatment of various allergic and inflammatory diseases of the body, as well as: adjunctive therapy in tuberculosis meningitis; treatment of trichinosis with neurologic or myocardial involvement; to induce the diuresis or remission of proteinuria in the nephrotic syndrome; symptomatic relief of ulcerative colitis or regional enteritis during critical periods; use as maintenance or during a flare-up of systemic lupus erythematosus, polymyositis, or rheumatic carditis; palliative management of leukemias and lymphomas in adults treatment of various anemias and thrombocytopenias; and treatment of various endocrine and respiratory disorders. Dosages vary between individuals and disease states: DOSAGES MUST BE INDIVIDUALIZED. Normal doses range from 4 mg to 48 mg per day. Constant patient monitoring is essential in proper therapy. In long-term Medrol therapy, alternate day dosing may be beneficial. Acute exacerbations of multiple sclerosis: 160 mg per day for 7 days followed by 64 mg every other day for one month. * Indications and Dosage Ranges for topical Medrol and injectable Depo-Medrol are not included on this card. See manufacturer's package insert for full prescribing information. Pharmacology Adrenocorticoids bind to certain receptor proteins found in the cytoplasm of sensitive cells to form a steroid-receptor complex. This steroid-receptor complex enters the nucleus of the cell where it reacts with chromatin, or DNA. The steroid, or possibly the receptor, then uses stored information to stimulate, or in some cases inhibit, the transcription of m-RNA. The stimulation of m-RNA results in the synthesis of specific proteins and ultimately specific enzymes that carry out its antiallergy and anti-inflammatory actions. Interactions May antagonize the effects of anticholinesterases. Barbiturates, rifampin, and hydantoins may increase metabolism. Estrogens may decrease metabolism. Ketoconazole may increase effects. May decrease salicylate effectiveness. Precautions Use is contraindicated in patients with systemic fungal infections. Use with caution in pregnancy and in patients with ocular herpes simplex, hypothyroidism, cirrhosis, ulcerative colitis, diverticulitis, fresh intestinal anastomoses, renal impairment, hypertension, osteoporosis, myasthenia gravis, tuberculosis, peptic ulcers, and diabetes mellitus. Patients on Medrol therapy should not undergo any form of immunization. Pregnancy Category C not assigned per manufacturer; however, similar agents like prednisolone are classified as "C" ; . Adverse Effects Blurred vision, upset stomach, nausea, vomiting, fluid and electrolyte disturbances, Cushing's syndrome, increased susceptibility to infections, osteoporosis, vertebral compression, various behavioral disturbances, peptic ulceration, myopathy, suppression of growth in children, and signs of adrenal suppression. Patient Consultation TOP 200 DRUGS of 2000 Page 86 of 87.
After the basal sample had been taken, eight subjects were given a meal low in phenylalanine and tyrosine, as described in Tables 1 and 2. Together with other normal dietary constituents, the meal contained rather large amounts of carbohydrates, for example, methylprednisolone therapy. BA, Murphy DL, Max MB. Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989; 37 2 ; : 223-7. 14. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330 13 ; : 896-900. 15. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Insitute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996; 125 5 ; 376-83. 16. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343 21 ; : 1514-9. 17. Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH. Association of pain relief with drug side effects in postherpetic neuralgia; A single-dose study of clonidine, codeine, ibuprofen, and placebo.Clin Pharmacol Ther 1988; 43 3 ; : 363-71. 18. Rowbotham MC, Reinser-Keller LA, Fields H. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41 7 ; : 1024-8. 19. Rowbotham MC, Harden N, Stacey B, Bernstein P Magnus-Miller L. , Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998; 280 21 ; : 1837-42. 20. Watson CPN, Evans RJ, Watt VR. Postherpetic neuralgia and topical capsaicin. Pain 1988; 33 3 ; : 333-40. 21. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995; 37 2 ; : 246-53. 22. Winnie AP Hartwell PW. Relationship , between time of treatment of acute herpes zoster with sympathetic blockade and prevention of postherpetic neuralgia: Clinical support for a new theory of the mechanism by which sympathetic blockade provides therapeutic benefit. Reg Anesth 1993; 18 5 ; : 277-82. 23. Rowbotham MC, Taylor K. Herpes zoster and postherpetic neuralgia. In: Yaksh TC, Lynch C, Zapol WM, et al eds ; . Anesthesia: Biologic foundations. Philadephia: Lippincott-Raven, 1998: 879-88. Literature retrieval Relevant articles were identified by searching PubMed using the key phrases hypercytokinaemia, inflammation, steroids or corticosteroids, in combination with the terms influenza, avian influenza or H5N1. In addition, the drug terms methylprednisolone and hydrocortisone, in combination with influenza terms were also searched, as well as the terms sepsis and steroids, and cortisol, adrenocorticotropin hormone ACTH ; and influenza. Papers cited from articles retrieved in the initial search were also reviewed. Hypercytokinaemia Cytokine families and functions Cytokines are signalling proteins involved in the response to pathogens and subsequent inflammatory processes. Of the six classes, the interferons IFNs ; , interleukins ILs ; and tumour necrosis factors are the most important. A clinical and experimentally useful classification system divides cytokines into those that promote the proliferation and function of T-helper type 1 cells and those that do the same for T-helper type 2 cells. Examples of Th-1 cytokines include IL-1 and IFN-c, and examples of Th-2 cytokines include IL-4, IL-10, IL-13 and TGF-b. The IFN family comprises several types: type I, of which IFNa and IFN-b are the most well known, have antiviral activity. Topical immunomodulators, a nonsteroidal class of topical agents that are safer than corticosteroids, are the first new class of prescription drugs to be developed in more than 40 years for the treatment of ad.

Methylprednisolone information Be that this immunophilin plays a role in interacting with the signalling pathways regulated by glucocorticoids. We should also not forget that there are other regulatory co-factors, such as GRIP-1 glucocorticoid receptor interacting protein 1 ; and SRC1 steroid receptor co-activator 1 ; , that are recruited to activated GR and link with transcription machinery. The differential recruitment of these factors by other glucocorticoids is as yet unknown, but they may also have a significant role to play. How the timing of FK506 and glucocorticoid treatment may have such profound differences is also unknown. It might be reasonable to postulate that the kinetics of simultaneous FK506 plus glucocorticoid GR binding versus a pre-treatment strategy may have a different effect on immunophilin interchange. When used alone FK506 brings about nuclear localization of GR Figure 4 ; . The functional meaning of this is unclear. However, in this DNA-bound state the binding affinity of GR for glucocorticoid ligands may be increased, thus explaining the potentiation phenomenon seen in pre-treatment experimental scenarios. The glucocorticoid antagonist RU486 also brings about a melting of the GR complex and induces a nuclear localization. However, in this state GR is capped and glucocorticoid regulation of genomic effects is blocked. It would appear then that FK506 behaves in a manner contrary to glucocorticoid antagonists. Of the glucocorticoids tested here methyl-prednisolone seemingly behaves uniquely, since it does not induce nuclear uptake of GR and does not block IL-1 induction of COX2. This would therefore imply that this glucocorticoid elicits effects of cell growth and arachidonic acid release inhibition solely by nongenomic mechanisms. We have previously described that in A549 cells pre-treated with geldanamycin to prevent nuclear uptake of GR the inhibitory responses of dexamethasone remain unchecked [4]. It would therefore appear from this that a significant portion of glucocorticoid activity could be ascribed to non-genomic processes and this is most apparent with methylprednisolone. Clearly this must have implications for interpreting the apparent enhancement of glucocorticoid action in therapeutic use. The observations described here were performed in A549 cells in vitro. As glucocorticoids are of major clinical relevance in the treatment of many diseases, it is important to consider how the findings could be translated to a clinical setting. The first important clinical implication from the present study is that not all glucocorticoids are the same. A great variety of different types of glucocorticoid are now available to clinicians. Which glucocorticoids are.